JP2019509268A5 - - Google Patents

Download PDF

Info

Publication number
JP2019509268A5
JP2019509268A5 JP2018542755A JP2018542755A JP2019509268A5 JP 2019509268 A5 JP2019509268 A5 JP 2019509268A5 JP 2018542755 A JP2018542755 A JP 2018542755A JP 2018542755 A JP2018542755 A JP 2018542755A JP 2019509268 A5 JP2019509268 A5 JP 2019509268A5
Authority
JP
Japan
Prior art keywords
dihydrophthalazine
amino
pharmaceutical composition
dione
precipitate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018542755A
Other languages
English (en)
Japanese (ja)
Other versions
JP7034079B2 (ja
JP2019509268A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/000227 external-priority patent/WO2017140430A1/en
Publication of JP2019509268A publication Critical patent/JP2019509268A/ja
Publication of JP2019509268A5 publication Critical patent/JP2019509268A5/ja
Priority to JP2021192808A priority Critical patent/JP7331067B2/ja
Application granted granted Critical
Publication of JP7034079B2 publication Critical patent/JP7034079B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018542755A 2016-02-16 2017-02-15 5-アミノ-2,3-ジヒドロフタラジン-1,4-ジオンの結晶形の製造方法 Active JP7034079B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021192808A JP7331067B2 (ja) 2016-02-16 2021-11-29 5-アミノ-2,3-ジヒドロフタラジン-1,4-ジオンの結晶形

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16000379.4 2016-02-16
EP16000379 2016-02-16
PCT/EP2017/000227 WO2017140430A1 (en) 2016-02-16 2017-02-15 Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021192808A Division JP7331067B2 (ja) 2016-02-16 2021-11-29 5-アミノ-2,3-ジヒドロフタラジン-1,4-ジオンの結晶形

Publications (3)

Publication Number Publication Date
JP2019509268A JP2019509268A (ja) 2019-04-04
JP2019509268A5 true JP2019509268A5 (enExample) 2020-03-26
JP7034079B2 JP7034079B2 (ja) 2022-03-11

Family

ID=55398165

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018542755A Active JP7034079B2 (ja) 2016-02-16 2017-02-15 5-アミノ-2,3-ジヒドロフタラジン-1,4-ジオンの結晶形の製造方法
JP2021192808A Active JP7331067B2 (ja) 2016-02-16 2021-11-29 5-アミノ-2,3-ジヒドロフタラジン-1,4-ジオンの結晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021192808A Active JP7331067B2 (ja) 2016-02-16 2021-11-29 5-アミノ-2,3-ジヒドロフタラジン-1,4-ジオンの結晶形

Country Status (8)

Country Link
US (1) US11111218B2 (enExample)
EP (1) EP3416951B1 (enExample)
JP (2) JP7034079B2 (enExample)
KR (1) KR102535960B1 (enExample)
CN (2) CN115536594A (enExample)
CA (1) CA3011767C (enExample)
ES (1) ES2797299T3 (enExample)
WO (1) WO2017140430A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3511325A1 (en) 2018-01-11 2019-07-17 MetrioPharm AG Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
GB201804132D0 (en) * 2018-03-15 2018-05-02 Secr Defence Forensic analysis of an object for chemical and biological agents
EP3858358A1 (en) * 2020-01-31 2021-08-04 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases
EP3858328A1 (en) * 2020-01-31 2021-08-04 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseases
BR112022019141A2 (pt) * 2020-03-25 2023-01-17 Metriopharm Ag 5-amino-2,3-dihidro-1,4-ftalazinadiona para tratamento de lesão pulmonar aguda
EP3981405A1 (en) 2020-10-08 2022-04-13 MetrioPharm AG Compound for the treatment of coronaviral infections
CN116075306B (zh) 2020-06-10 2024-12-27 麦翠奥制药公司 用于治疗冠状病毒感染的化合物
CN116963738A (zh) 2020-12-02 2023-10-27 麦翠奥制药公司 用于SARS-CoV-2感染的后遗症的预防和治疗的鲁米诺
US20230087473A1 (en) * 2021-09-22 2023-03-23 Hemant N. Joshi Composition of suspoemulsion formulation of anthelmintic drugs with essential oils for naso-pulmonary administration
EP4193994A1 (en) 2021-12-08 2023-06-14 MetrioPharm AG Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections
IL313638A (en) * 2022-01-07 2024-08-01 Metriopharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of congenital muscular dystrophies
EP4209219A1 (en) * 2022-01-07 2023-07-12 MetrioPharm AG Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione
EP4248963A1 (en) 2022-03-25 2023-09-27 MetrioPharm AG Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a fumaric acid ester
EP4483879A1 (en) 2023-06-29 2025-01-01 MetrioPharm AG 5-amino-2,3-dihydro-1,4-phthalazinedione for the prophylaxis and treatment of thrombotic disorders
WO2025067689A1 (en) 2023-09-26 2025-04-03 Metriopharm Ag 5-amino-2,3-dihydro-1,4-phthalazinedione for the treatment of infections with an rna virus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH683966A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanze attive in agenti anti-ipossici e di difesa.
FR2839155B1 (fr) * 2002-04-25 2005-02-04 Roc Imp Procede pour detecter et localiser des traces de sang et compose pour detecter des traces de sang
EP2542535B1 (de) 2010-03-01 2014-05-07 MetrioPharm AG Kristalline formen von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
WO2011123776A2 (en) 2010-04-01 2011-10-06 Guthery B Eugene Method for detecting occult blood
CN107567437B (zh) * 2014-12-18 2020-11-17 麦翠奥制药公司 5-氨基-2,3-二氢酞嗪-1,4-二酮钠盐的晶形、含其的药物制剂及其生产方法

Similar Documents

Publication Publication Date Title
JP2019509268A5 (enExample)
JP2018035160A5 (enExample)
JP2005501074A (ja) パロキセチン・グリチルリチン酸塩
JP2018516883A5 (enExample)
HU227589B1 (en) Crystal form of (s)-omeprazole
JP2012507496A (ja) レナリドマイドの結晶形およびその調製方法
US10556915B2 (en) Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations
JP6452698B2 (ja) バンコマイシン誘導体、その製造方法及び応用
WO2020135058A1 (zh) 罗沙司它的新晶型及其制备方法
PT108978B (pt) Sais de tetraciclinas
CN105726487A (zh) 一种高含量阿莫西林可溶性粉剂制备方法及应用
JP2017515821A5 (enExample)
CN105189513A (zh) 葡萄糖醇,1-脱氧-1-(甲胺基)-,1-(6-氨基-3,5-二氟吡啶-2-基)-8-氯-6-氟-1,4-二氢-7-(3-羟基氮杂环丁烷-l-基)-4-氧-3-喹啉羧酸盐的结晶形态
WO2018109786A1 (en) Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
CN102471273B (zh) 2-[[[2-[(羟基乙酰基)氨基]-4-吡啶基]甲基]硫代]-n-[4-(三氟甲氧基)苯基]-3-吡啶甲酰胺苯磺酸盐、其晶体、其多晶型物以及用于制备其的方法
JP2005529084A5 (enExample)
JP2005529084A (ja) 結晶性パレコキシブナトリウム
JP2019529553A5 (enExample)
JP6694029B2 (ja) 3−ホルミルリファマイシンsv及び3−ホルミルリファマイシンsの3−(4−シンナミル−1−ピペラジニル)アミノ誘導体を含有する医薬製剤並びにこれらの製造方法
EP1844017A1 (en) An amorphous and three crystalline forms of rimonabant hydrochloride
TW201247681A (en) Process for purifying staurosporine
CN102204916B (zh) 一种含头孢美唑钠化合物的药物组合物及其制备方法
CN104910147B (zh) 阿哌沙班晶体及其制备方法
JP2015504913A (ja) 安定な非晶質のラルテグラビルカリウムプレミックス、及び、その調製方法
JP2009536638A (ja) アトルバスタチンマグネシウムの結晶性形状b4及びその方法